Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
6 min read
Rappta Therapeutics Oy Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Rappta Therapeutics Oy 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
RAYNOVENT Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
RAYNOVENT Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Rescue Hearing, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Rescue Hearing, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Regulus Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Regulus Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
PolTREG SA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
PolTREG SA 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Quiver Bioscience, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Quiver Bioscience, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Rani Therapeutics Holdings, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Rani Therapeutics Holdings, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
6 min read
Quotient Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Quotient Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Polpharma Biologics S.A. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Polpharma Biologics S.A. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Pfizer Pharmaceuticals Korea Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Pfizer Pharmaceuticals Korea Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Phrontline Biopharma (Suzhou) Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Phrontline Biopharma (Suzhou) Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Pharos iBio Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Pharos iBio Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
<
1
<<
216
217
218
219
220
>>
1503
>